Ganetespib

DB12047InvestigationalSmall molecule

Ganetespib is under investigation for the treatment of BREAST CANCER, Small Cell Lung Cancer, Acute Myeloid Leukaemia, and Myelodysplastic Syndrome.

Mechanism: Pharmacologically active on Heat shock protein HSP 90-alpha and Heat shock protein HSP 90-beta
Curator reviewed
Formula / weight: C₂₀H₂₀N₄O₃ · 364.3978 g/mol (avg)
Code names: STA-9090

Resolves to

Compound

Structure

InChIKeyRVAQIUULWULRNW-UHFFFAOYSA-NSMILESCC(C)C1=C(O)C=C(O)C(=C1)C1=NNC(=O)N1C1=CC2=C(C=C1)N(C)C=C2

Targets

What you can answer from here — as of July 07, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

37Clinical trialsPhase, status and sponsor resolved per trial

8+ReferencesStructured and connected to the statements they support

Which drugs share a target with Ganetespib, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.